TRED-HF Trial (2019): Withdrawal of treatment for HF in patients with recovered DCM

TRED-HF visual abstract

TRED-HF Trial Summary: Halliday et al. randomized 51 patients with dilated cardiomyopathy (LVEF<40%) who recovered with the improvement of symptoms to either continual treatment with HF medications or withdrawal of HF therapy. The objective was to assess the safety of withdrawing treatment in patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered. The results showed significant replase of HF in patients who were taken of HF management. (P <0.0001) The authors of TRED-HF trial concluded that withdrawal of HF medications among patients with DCM who had recovered their LV function results in relapse of HF, and should probably be avoided indefinitely unless necessary.

Source: Lancet